• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Construction and synthesis of tricyclic matrinic derivatives against influenza A virus by privileged structure strategy

tetano

Editor, Senior Moderator
Pharmazie. 2019 May 1;74(5):265-269. doi: 10.1691/ph.2019.8968.
[h=1]Construction and synthesis of tricyclic matrinic derivatives against influenza A virus by privileged structure strategy.[/h] Jiang J, Zhao X, Niu T, Yan H, Yinghong LI, Yuhuan LI, Song D, Tang S, Xing J.
[h=3]Abstract[/h] A series of new matrinic derivatives with an 11-adamantyl group were designed, synthesized and evaluated for their anti-influenza A H3N2 activities, based on the privileged structure strategy.SAR analysis indicated that introduction of an 11-adamantyl by ester linker might be helpful for the activity. Among them, compound 7b exhibited promising anti-H3N2 activities with IC[SUB]50[/SUB] value of 5.14 μM, slightly better than that of amantadine. Its activity was further confirmed at the protein level. In primary mechanism, compound 7b could inhibit virus replication cycle at early stage by targeting M2 protein, consistent with that of amantadine. This study represents a successful application of combined strategy of privileged amantadine segment for further structural optimization and development of a new class of anti-influenza agents.


PMID: 31109395 DOI: 10.1691/ph.2019.8968
 
Back
Top Bottom